Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's Net Income towards Common Stockholders fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 25.75%. This contributed to the annual value of -$305.8 million for FY2024, which is 186.31% down from last year.
  • As of Q3 2025, Immunome's Net Income towards Common Stockholders stood at -$60.1 million, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Net Income towards Common Stockholders peaked at -$4.3 million during Q3 2023, and registered a low of -$132.3 million during Q1 2024.
  • For the 3-year period, Immunome's Net Income towards Common Stockholders averaged around -$51.3 million, with its median value being -$46.5 million (2025).
  • In the last 5 years, Immunome's Net Income towards Common Stockholders tumbled by 2,859.05% in 2024 and then spiked by 66.26% in 2025.
  • Over the past 3 years, Immunome's Net Income towards Common Stockholders (Quarterly) stood at -$92.6 million in 2023, then grew by 10.43% to -$83.0 million in 2024, then declined by 19.03% to -$60.1 million in 2025.
  • Its last three reported values are -$60.1 million in Q3 2025, -$46.5 million for Q2 2025, and -$44.6 million during Q1 2025.